SYVA announces its partnership with the biotech SMIVET for the development of SDA [SDA]
SYVA announces its partnership with the biotech SMIVET for the development of single-domain antibody-based solutions in animal health.
León – Technology Park – Spain, March 2, 2023 – SYVA and SMIVET signed a collaboration agreement that allow both companies to develop therapeutic solutions based on Single Domain Antibodies (SDA). With this agreement, Syva expresses its willingness to invest in new biotechnologies with the objective to continue to grow and improve its attractiveness by researching, developing, and producing innovative and meaningful solutions for the animal health sector.
By signing such a collaboration agreement* with the biotech company SMIVET, SYVA opens many new horizons in terms of developing targeted bio-therapeutic solutions in both the livestock and companion animal sectors.
Thanks to regular investments over the years, Syva is well equipped with state-of-the-art facilities and ensures that all stages of the development and production of its veterinary medicines are within the best practices. This is achieved primarily by researching and analysing development opportunities within its R&D department.
“To ensure that we remain competitive and attractive in our sector of activity, we must continue to be committed to researching, innovating and investing in new technological development of our production sites. With this state of mind, we decided to focus on Single Domain Antibodies, and, after an in-depth analysis of our mutual development capabilities, we chose the biotech company SMIVET as partner and new driver of our strategic evolution,”said César Carnicer, Managing Director of Syva Laboratories.
Since 2013, SMIVET has developed its own supportive SDA platform and it’s pipeline libraries enables the development of new biotherapeutics solutions to treat diseases in companion animals as well as in livestock.
““Single-domain antibodies or nanobodies, in addition to being a rapidly growing innovative field, offer many development opportunities in the treatment of a broad range of infectious, inflammatory, degenerative and chronic diseases in animals. Their small size, high specificity and low immunogenicity allow for many applications with high efficiency,”, said Dr (PHD) Hans de Smit.
SYVA and SMIVET, are both family-owned companies. Hans de Smit, Founder and Managing Director of SMIVET and César Carnicer, General Manager of SYVA, are both veterinarian with a strong veterinary pharmaceutical industry back-ground and this collaboration is based on a strategic match.
*The terms of the transaction are not disclosed
ABOUT SMIVET
SMIVET BV is a veterinary biotech company founded in 2013 in the Netherlands. The R&D activities came up to speed from end of 2014 onwards when the company decided to focus on the technology of Single Domain Antibodies (SDAs) and develop a suitable supportive SDA platform for use in multiple animal species. Its actual research pipeline is based on several proprietary SDA libraries with the purpose to introduce new innovative bio-therapeutics for the treatment of diseased cats, dogs, horses, fish, and livestock.
The research efforts are supported by a network of specialists from academia and the industry.
For more information about SMIVET : https://smivet.com
ABOUT SYVA
Since its foundation in 1941, the Spanish company Laboratorios Syva has been committed to researching opportunities and to scientific based development to innovate and offer efficient solutions for the animal health sector. This capacity to adapt drives the company’s strategy to grow and to maintain state-of-the-art bioengineering and manufacturing facilities to produce vaccines, first-line anti-infectives and other essential medicines for animal health and welfare, which are distributed in nearly 70 countries worldwide.
For more information about Syva: https://syva.es
Downloads
You may also be interested in
30 January, 2025
Syvac® EH Marker, the first and only DIVA vaccine against EHD, is now authorized in Belgium
Syva is pleased to announce that the FAMHP/FAGG has granted emergency use authorization for its marker (DIVA) vaccine against EHD in accordance with Article 110(2) of Regulation (EU) 2019/6 for use in cattle and deer.
24 January, 2025
Call for the 28th edition of the Syva Award International for the best doctoral thesis in Animal Health
We are pleased to remind you that the call for applications for the 28th Syva Award International is open until 18 February 2025. We also remind you that for two years now, the Syva Award International is no longer limited to Spanish candidates, but invites all doctoral students of any nationality who have submitted their thesis in animal health...
22 January, 2025
Syva receives a positive opinion for Syvazul BTV 3 vaccine from the CVMP of the European Medicines Agency (EMA).
On 15 January 2025, the Committee for Medicinal Products for Veterinary Use (CVMP) issued a positive opinion recommending the granting of a marketing authorization for Syvazul BTV 3 vaccine. This step forward marks an important milestone in the fight against Bluetongue, and Syva is proud to be at the forefront of this innovation.
Media tool kit
We provide users, particularly journalists and the press, with a series of graphic documents, photographs and videos. We offer the free use of these documents under certain conditions
Journalist and Press Contact
Are you a journalist, part of the press or the media? Do you want to get information on our activities, validate your sources in a professional manner, obtain validated photographic material or request an interview?
Next Events
